← back to search

Sudarshan Paramsothy

The University of Sydney · AU
Area of research
Genetics · Molecular Biology
Research interest
Research interests include Inflammatory Bowel Disease, Gut microbiota and health, Microscopic Colitis, and Clostridium difficile and Clostridium perfringens research.
h-index
30
citations
5,051
works
166
NIH funding
primary concept
email

Recent publications

Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference
Inflammatory Bowel Diseases 2025cited by 14position: middledoi
International consensus statement on microbiome testing in clinical practice
˜The œLancet. Gastroenterology & hepatology 2024cited by 70position: middledoi
Gut microbiota strain richness is species specific and affects engraftment
Nature 2024cited by 52position: middledoi
Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Journal of Crohn s and Colitis 2024cited by 19position: middledoi
The phageome of patients with ulcerative colitis treated with donor fecal microbiota reveals markers associated with disease remission
Nature Communications 2024cited by 15position: middledoi
Refining microbial community metabolic models derived from metagenomics using reference-based taxonomic profiling
mSystems 2024cited by 5position: middledoi
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease
Gut 2023cited by 118position: middledoi
Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics
Cell Reports Medicine 2022cited by 106position: middledoi
Microbial determinants of effective donors in faecal microbiota transplantation for UC
Gut 2022cited by 53position: middledoi
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
Therapeutic Advances in Gastroenterology 2022cited by 37position: middledoi
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial
˜The œLancet. Gastroenterology & hepatology 2021cited by 256position: middledoi
Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study
Alimentary Pharmacology & Therapeutics 2021cited by 78position: middledoi
Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis
The American Journal of Gastroenterology 2021cited by 34position: middledoi
Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study
BMJ Open 2021cited by 16position: middledoi
Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis
Cell Host & Microbe 2020cited by 171position: middledoi
Defined microbiota transplant restores Th17/RORγt <sup>+</sup> regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas
Proceedings of the National Academy of Sciences 2020cited by 106position: middledoi
Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice
Gut 2020cited by 101position: middledoi
Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis
Gastroenterology 2018cited by 520position: firstdoi
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial
The Lancet 2017cited by 1,236position: firstdoi
Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Journal of Crohn s and Colitis 2017cited by 422position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Rupert W. Leong · Macquarie University12 papers (2017–2024)Nadeem O. Kaakoush · UNSW Sydney10 papers (2017–2024)Thomas J. Borody · Centre For Digestive Diseases9 papers (2017–2024)Michael A. Kamm · Victorian Aboriginal Health Service7 papers (2017–2024)Craig Haifer · The Catholic University of Korea St. Vincent's Hospital5 papers (2020–2024) · 5 papers (2017–2021)Hazel M. Mitchell · UNSW Sydney5 papers (2017–2020)Susan J. Connor · Crohn's and Colitis UK4 papers (2017–2021)Jean‐Frédéric Colombel · Cornell University3 papers (2018–2020)Laurence Don Wai Luu · University of Technology Sydney3 papers (2021–2024)Simon Ghaly · UNSW Sydney3 papers (2020–2021)Jeremiah J. Faith · Mount Sinai Health System3 papers (2018–2020)José C. Clemente · SK Life Science (United States)3 papers (2018–2020) · 2 papers (2020–2023)Yanna Ko · Western Sydney University2 papers (2021–2022)Watson Ng · UNSW Sydney2 papers (2017–2018)Daniel A. Lemberg · UNSW Sydney2 papers (2020–2021)Yvonne Tran · Macquarie University2 papers (2021–2024)Enmoore Lin · UNSW Sydney2 papers (2017–2018)Marwan E. Majzoub · UNSW Sydney2 papers (2024–2024)